TYRA Logo

Tyra Biosciences, Inc. (TYRA) 

NASDAQ
Market Cap
$801.3M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
21 of 775
Rank in Industry
18 of 433

Largest Insider Buys in Sector

TYRA Stock Price History Chart

TYRA Stock Performance

About Tyra Biosciences, Inc.

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company …

Insider Activity of Tyra Biosciences, Inc.

Over the last 12 months, insiders at Tyra Biosciences, Inc. have bought $19.99M and sold $11.52M worth of Tyra Biosciences, Inc. stock.

On average, over the past 5 years, insiders at Tyra Biosciences, Inc. have bought $31.09M and sold $12M worth of stock each year.

Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $495.9M. Fuhrman Alan (Chief Financial Officer) — $151,954.

The last purchase of 1,220,681 shares for transaction amount of $19.84M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑11‑08.

List of Insider Buy and Sell Transactions, Tyra Biosciences, Inc.

2024-11-08Purchase
1.22M
2.3305%
$16.25$19.84M-1.89%
2024-11-07Saledirector
22,091
0.0422%
$17.32$382,574-7.46%
2024-11-06Saledirector
52,491
0.1004%
$17.18$901,559-7.10%
2024-11-05Saledirector
10,493
0.0203%
$16.77$175,9500.00%
2024-11-04Saledirector
1,076
0.0021%
$17.01$18,298-2.92%
2024-11-01Saledirector
27,493
0.0527%
$16.56$455,272-2.23%
2024-10-31Saledirector
100,140
0.1874%
$16.46$1.65M-3.42%
2024-10-30Saledirector
11,078
0.0213%
$16.17$179,120+1.25%
2024-10-30PurchaseChief Financial Officer
9,500
0.018%
$16.00$151,954+1.25%
2024-10-21SalePresident and CEO
19,084
0.0356%
$27.90$532,451-43.00%
2024-10-18SalePresident and CEO
43,636
0.0818%
$27.01$1.18M-40.61%
2024-10-17SalePresident and CEO
15,394
0.029%
$25.85$397,872-37.22%
2024-10-16SalePresident and CEO
33,297
0.0706%
$26.17$871,430-36.72%
2024-10-15SalePresident and CEO
10,035
0.0198%
$24.31$243,970-32.93%
2024-09-30SalePresident and CEO
500
0.001%
$24.00$12,000-11.36%
2024-09-25SalePresident and CEO
600
0.0012%
$24.01$14,406-2.54%
2024-09-24SalePresident and CEO
1,055
0.002%
$24.02$25,341-2.58%
2024-09-23SalePresident and CEO
10,092
0.0195%
$24.13$243,477-11.25%
2024-09-20SalePresident and CEO
7,109
0.0134%
$24.19$171,950-13.24%
2024-09-19SalePresident and CEO
5,698
0.0109%
$24.31$138,491-11.25%

Insider Historical Profitability

<0.0001%
RA CAPITAL MANAGEMENT, L.P.
8697956
17.1886%
$15.8420<0.0001%
Fuhrman AlanChief Financial Officer
12849
0.0254%
$15.8410
Boxer Capital, LLC10 percent owner
6448359
12.743%
$15.8420<0.0001%
MORE ROBERT Jdirector
4080296
8.0633%
$15.8410<0.0001%
Alta Partners NextGen Fund II Management, LLC10 percent owner
4080296
8.0633%
$15.8410<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
RA Capital Management, L.P.$170.83M19.8310.42M+43.95%+$52.15M0.17
Boxer Capital, LLC$105.75M12.276.45M0%+$02.17
Bvf Inc Il$76.44M8.874.66M+70.14%+$31.51M0.56
Canaan Partners Xi Llc$72.32M8.394.41M0%+$079.77
Nextech Invest$66.52M7.724.06M+61.04%+$25.21M10.85
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.